Neo Kuma Ventures invests in early stage psychedelic healthcare companies at the forefront of clinical research into illnesses including depression, PTSD, addiction, inflammation and chronic pain. By working with the leading companies in this field we will advance and redefine the standard of patient care. Our fund invests in pre-seed to series A, where we can play a valuable role as investors. For more information please email info@neokuma.co